Evasion of innate and adaptive immunity by flaviviruses

Immunology and Cell Biology

Volumn 81, Issue 3, 2003, Pages 196-206

  Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Encephalitis; Immune response; Pathogenesis; RNA virus

Indexed keywords

ANTIVIRUS AGENT; VIRUS RNA;

ACUTE DISEASE; ANTIBODY PRODUCTION; ANTIVIRAL ACTIVITY; COMPLEMENT ACTIVATION; DISEASE COURSE; DISEASE MODEL; DRUG DESIGN; ERADICATION THERAPY; FLAVIVIRUS; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFECTION CONTROL; INTERFERON PRODUCTION; NATURAL KILLER CELL; NONHUMAN; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; VIROGENESIS; VIRUS ENCEPHALITIS; VIRUS INFECTION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANIMALS; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; INSECT VECTORS; INSECT VIRUSES;

ANIMALIA; FLAVIVIRUS; RNA VIRUSES;

EID: 0037899939     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.2003.01157.x     Document Type: Review

References (187)

1. Burke DS, Monath TP. Flaviviruses In: Knipe DM, Howley PM, eds. Fields Virology, 4th edn, Vol. 1. Philadelphia: Lippincott Williams & Wilkins, 2001; 1043-125.
2. Lindenbach BD, Rice CM. Flaviviridae: The viruses and their replication In: Knipe DM, Howley PM, eds. Fields Virology, Vol. 1. Philadelphia: Lippincott Williams & Wilkins, 2001; 991-1041.
3. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 1990; 44: 649-88.
4. Gollins S, Porterfield J. The uncoating and infectivity of the flavivirus West Nile on interaction with cells: effects of pH and ammonium chloride. J. Gen. Virol. 1986; 67: 1941-50.
5. Kimura T, Gollins SW, Porterfield JS. The effect of pH on the early interaction of West Nile virus with P388D1 cells. J. Gen. Virol. 1986; 67: 2423-33.
6. Falgout B, Markoff L. Evidence that flavivirus NS1-NS2A cleavage is mediated by a membrane-bound host protease in the endoplasmic reticulum. J. Virol. 1995; 69: 7232-43.
7. Markoff L, Chang A, Falgout B. Processing of flavivirus structural glycoproteins: stable membrane insertion of premembrane requires the envelope signal peptide. Virology 1994; 204: 526-40.
8. Ogawa M, Okubo H, Tsuji Y, Yasui N, Someda K. Chronic progressive encephalitis occurring 13 years after Russian spring-summer encephalitis. J. Neurol. Sci. 1973; 19: 363-73.
9. Sharma S, Mathur A, Prakash V, Kulshreshtha R, Kumar R, Chamrvedi UC. Japanese encephalitis virus latency in peripheral blood lymphocytes and recurrence of infection in children. Clin. Exp. Immunol. 1991; 85: 85-9.
10. Ho LJ, Wang JJ, Shaio MF et al. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J. Immunol. 2001; 166: 1499-506.
11. Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J. Virol. 2001; 75: 3501-8.
12. Marovich M, Grouard-Vogel G, Louder M et al. Human dendritic cells as targets of dengue virus infection. J. Invest. Dermatol. Symp. Proc. 2001; 6: 219-24.
13. Wu SJ, Grouard-Vogel G, Sun W et al. Human skin Langerhans cells are targets of dengue virus infection. Nat. Med. 2000; 6: 816-20.
14. Johnston LJ, Halliday GM, King NJ. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J. Invest. Dermatol. 2000; 114: 560-8.
15. Zeidner NS, Higgs S, Happ CM, Beaty BJ, Miller BR. Mosquito feeding modulates Th1 and Th2 cytokines in flavivirus susceptible mice: an effect mimicked by injection of sialokinins, but not demonstrated in flavivirus resistant mice. Parasite Immunol. 1999; 21: 35-44.
16. Kubes M, Fuchsberger N, Labuda M, Zuffova E, Nuttall PA. Salivary gland extracts of partially fed Dermacentor reticulatus ticks decrease natural killer cell activity in vitro. Immunology 1994; 82: 113-6.
17. Kubes M, Kocakova P, Slovak M, Slavikova M, Fuchsberger N, Nuttall PA. Heterogeneity in the effect of different ixodid tick species on human natural killer cell activity. Parasite Immunol. 2002; 24: 23-8.
18. Hajnicka V, Kocakova P, Slovak M, Labuda M, Fuchsberger N, Nuttall PA. Inhibition of the antiviral action of interferon by tick salivary gland extract. Parasite Immunol. 2000; 22: 201-6.
19. Labuda M, Jones LD, Williams T, Nuttall PA. Enhancement of tick-borne encephalitis virus transmission by tick salivary gland extracts. Med. Vet. Entomol. 1993; 7: 193-6.
20. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 2003; 77: 2578-86.
21. Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr. Top. Microbiol. Immunol. 2002; 267: 171-94.
22. Xiao SY, Guzman H, Zhang H, Travassos da Rosa AP, Tesh RB. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg. Infect. Dis. 2001; 7: 714-21.
23. Xiao SY, Zhang H, Guzman H, Tesh RB. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J. Infect. Dis. 2001; 183: 1437-44.
24. Johnson RT, Mims CA. Pathogenesis of viral infections of the nervous system. N. Engl. J. Med. 1968; 278: 23-30 (contd).
25. Johnson RT, Mims GA. Pathogenesis for viral infections of the nervous system. N. Engl. J. Med. 1968; 278: 84-92 (concl).
26. Johnson RT. Viral Infections of the Nervous System. New York: Raven Press, 1982.
27. Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg. Infect. Dis. 2002; 8: 107-8.
28. Diamond M, Roberts T, Edgil D, Lu B, Ernst J, Harris E. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J. Virol. 2000; 74: 4957-66.
29. Diamond MS, Harris E. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology 2001; 289: 297-311.
30. Lin YL, Huang YL, Ma SH et al. Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication. J. Virol. 1997; 71: 5227-35.
31. Brooks TJ, Phillpotts RJ. Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res. 1999; 41: 57-64.
32. Stephen EL, Sammons ML, Pannier WL, Baron S, Spertzel RO, Levy HB. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J. Infect. Dis. 1977; 136: 122-6.
33. Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J. Virol. 1999; 73: 783-6.
34. Liu T, Chambers TJ. Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes. J. Virol. 2001; 75: 2107-18.
35. Lobigs M, Mulbacher A, Wang Y, Pavy M, Lee E. Role of type I and type II interferon responses in recovery from infection with an encephalitic flavivirus. J. Gen. Virol. 2003; 84: 567-72.
36. Sangster MY, Urosevic N, Mansfield JP, Mackenzie JS, Shellam GR. Mapping the Flv locus controlling resistance to flaviviruses on mouse chromosome 5. J. Virol. 1994; 68: 448-52.
37. Urosevic N, Mansfield JP, Mackenzie JS, Shellam GR. Low resolution mapping around the flavivirus resistance locus (Flv) on mouse chromosome 5. Mamm. Genome 1995; 6: 454-8.
38. Damell MB, Koprowski H. Genetically determined resistance to infection with group B arboviruses. II. Increased production of interfering particles in cell cultures from resistant mice. J. Infect. Dis. 1974; 129: 248-56.
39. Darnell MB, Koprowski H, Lagerspetz K. Genetically determined resistance to infection with group B arboviruses. I. Distribution of the resistance gene among various mouse populations and characteristics of gene expression in vivo. J. Infect. Dis. 1974; 129: 240-7.
40. Mashimo T, Lucas M, Simon-Chazottes D et al. A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc. Natl Acad. Sci. USA 2002; 99: 11 311-16.
41. Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. Positional cloning of the murine flavivirus resistance gene. Proc. Natl Acad. Sci. USA 2002; 99: 9322-7.
42. Brinton MA, Arnheiter H, Haller O. Interferon independence of genetically controlled resistance to flaviviruses. Infect. Immun. 1982; 36: 284-8.
43. Heinz FX, Berger R, Tuma W, Kunz C. A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies. Virology 1983; 126: 525-37.
44. Henchal EA, Henchal LS, Schlesinger JJ. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J. Gen. Virol. 1988; 69: 2101-7.
45. Kaufman BM, Summers PL, Dubois DR et al. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 1989; 41: 576-80.
46. Kimura-Kuroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol. 1988; 141: 3606-10.
47. Mason PW, Dalrymple JM, Gentry MK et al. Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J. Gen. Virol. 1989; 70: 2037-49.
48. Roehrig JT, Staudinger LA, Hunt AR, Mathews JH, Blair CD. Antibody prophylaxis and therapy for flaviviral encephalitis infections. Ann. NY Acad. Sci. 2001; 951: 286-97.
49. Schlesinger JJ, Brandriss MW, Walsh EE. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J. Immunol. 1985; 135: 2805-9.
50. Schlesinger JJ, Chapman S. Neutralizing F (ab′) 2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J. Gen. Virol. 1995; 76: 217-20.
51. Charlier NP, Leyssen J, Paeshuyse C et al. Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis. J. Gen. Virol. 2002; 83: 1887-96.
52. Halevy M, Akov Y, Ben-Nathan D, Kobiler D, Lachmi B, Lustig S. Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice. Arch. Virol. 1994; 137: 355-70.
53. Colombage G, Hall R, Pavy M, Lobigs M. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 1998; 250: 151-63.
54. Falconar AK. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch. Virol. 1999; 144: 2313-30.
55. Pincus S, Mason PW, Konishi E et al. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 1992; 187: 290-7.
56. Vazquez S, Guzman MG, Guillen G et al. Immune response to synthetic peptides of dengue prM protein. Vaccine 2002; 20: 1823-30.
57. Despres P, Dietrich J, Girard M, Bouloy M. Recombinant baculo-viruses expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice. J. Gen. Virol. 1991; 72: 2811-16.
58. Falgout B, Bray M, Schlesinger JJ, Lai CJ. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J. Virol. 1990; 64: 4356-63.
59. Putnak JR, Schlesinger JJ. Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J. Gen. Virol. 1990; 71: 1697-702.
60. Schlesinger JJ, Brandriss MW, Cropp CB, Monath TP. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J. Virol. 1986; 60: 1153-5.
61. Schlesinger JJ, Brandriss MW, Putnak JR, Walsh EE. Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody. J. Gen. Virol. 1990; 71: 593-9.
62. Schlesinger JJ, Brandriss MW, Walsh EE. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J. Gen. Virol. 1987; 68: 853-7.
63. Gould EA, Buckley A, Barrett AD, Cammack N. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J. Gen. Virol. 1986; 67: 591-5.
64. Volanakis JE. The role of complement in innate and adaptive immunity. Curr. Top. Microbiol. Immunol. 2002; 266: 41-56.
65. Ochsenbein AF, Zinkernagel RM. Natural antibodies and complement link innate and acquired immunity. Immunol. Today 2000; 21: 624-30.
66. Da Costa XJ, Brockman MA, Alicot E et al. Humoral response to herpes simplex virus is complement-dependent. Proc. Natl Acad. Sci. USA 1999; 96: 12 708-12.
67. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat. Med. 2002; 8: 373-8.
68. Ochsenbein AF, Pinschewer DD, Odermatt B, Carroll MC, Hengartner H, Zinkernagel RM. Protective T cell-independent antiviral antibody responses are dependent on complement. J. Exp. Med. 1999; 190: 1165-74.
69. Douglas MW, Kesson AM, King NJ. CTL recognition of west Nile virus-infected fibroblasts is cell cycle dependent and is associated with virus-induced increases in class I MHC antigen expression. Immunology 1994; 82: 561-70.
70. Kesson AM, Blanden RV, Mullbacher A. The primary in vivo murine cytotoxic T cell response to the flavivirus, West Nile. J. Gen. Virol. 1987; 68: 2001-6.
71. Kulkarni AB, Mullbacher A, Blanden RV. In vitro T-cell proliferative response to the flavivirus, West Nile. Viral Immunol. 1991; 4: 73-82.
72. Kurane I, Brinton MA, Samson AL, Ennis FA. Dengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones. J. Virol. 1991; 65: 1823-8.
73. Kurane I, Ennis FA. Cytotoxic T lymphocytes in dengue virus infection. Curr. Top. Microbiol. Immunol. 1994; 189: 93-108.
74. Kurane I, Innis BL, Hoke CH et al. T cell activation in vivo by dengue virus infection. J. Clin. Lab. Immunol. 1995; 46: 35-40.
75. Kurane I, Innis BL, Nisalak A et al. Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production. J. Clin. Invest. 1989; 83: 506-13.
76. Liu Y, Blanden RV, Mullbacher A. Identification of cytolytic lymphocytes in West Nile virus-infected murine central nervous system. J. Gen. Virol. 1989; 70: 565-73.
77. Murali-Krishna K, Ravi V, Manjunath R. Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells. J. Gen. Virol. 1996; 77: 705-14.
78. Takada K, Masaki H, Konishi E, Takahashi M, Kurane I. Definition of an epitope on Japanese encephalitis virus (JEV) envelope protein recognized by JEV-specific murine CD8+ cytotoxic T lymphocytes. Arch. Virol. 2000; 145: 523-34.
79. Camenga DL, Nathanson N, Cole GA. Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J. Infect. Dis. 1974; 130: 634-41.
80. Cole GA, Nathanson N. Potentiation of experimental arbovirus encephalitis by immunosuppressive doses of cyclophosphamide. Nature 1968; 220: 399-401.
81. Nathanson N, Cole GA. Fatal Japanese encephalitis virus infection in immunosuppresed spider monkeys. Clin. Exp. Immunol. 1970; 6: 161-6.
82. Nathanson N, Cole GA. Immunosuppression and experimental virus infection of the nervous system. Adv. Virus Res. 1970; 16: 397-448.
83. Nathanson N, Cole GA. Immunosuppression: a means to assess the role of the immune response in acute virus infections. Fed. Proc. 1971; 30: 1822-30.
84. Licon Luna RM, Lee E, Mullbacher A, Blanden RV, Langman R, Lobigs M. Lack of both Fas ligand and perforin protects from flavivirus-mediated encephalitis in mice. J. Virol. 2002; 76: 3202-11.
85. Kurane I, Ennis FE. Immunity and immunopathology in dengue virus infections. Semin. Immunol. 1992; 4: 121-7.
86. Rothman AL, Ennis FA. Immunopathogenesis of Dengue hemorrhagic fever. Virology 1999; 257: 1-6.
87. Monath TP, Brinker KR, Chandler FW, Kemp GE, Cropp CB. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am. J. Trop. Med. Hyg. 1981; 30: 431-43.
88. La Russa VF, Innis BL. Mechanisms of dengue virus-induced bone marrow suppression B. Bailieres Clin. Haematol. 1995; 8: 249-70.
89. Rothwell SW, Putnak R, La Russa VF. Dengue-2 virus infection of human bone marrow: characterization of dengue-2 antigen-positive stromal cells. Am. J. Trop. Med. Hyg. 1996; 54: 503-10.
90. Samuel CE. Antiviral actions of interferon: Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991; 183: 1-11.
91. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J. Virol. 1999; 73: 8469-75.
92. Gale M Jr, Blakely CM, Kwieciszewski B et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell Biol. 1998; 18: 5208-18.
93. Gale M Jr, Katze MG. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol. Ther. 1998; 78: 29-46.
94. Gale MJ Jr, Korth MJ, Katze MG. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin. Diagn. Virol. 1998; 10: 157-62.
95. Gale MJ Jr, Korth MJ, Tang NM et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-27.
96. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-10.
97. Bass BL. Double-stranded RNA as a template for gene silencing. Cell 2000; 101: 235-8.
98. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8.
99. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001; 15: 188-200.
100. Zamore PD, Tuschl T, Sharp PA, Bagel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21-23 nucleotide intervals. Cell 2000; 101: 25-33.
101. Baulcombe D. RNA silencing: Diced defence. Nature 2001; 409: 295-6.
102. Lindbo JA, Fitzmaurice WP, della-Cioppa G. Virus-mediated reprogramming of gene expression in plants. Curr. Opin. Plant Biol. 2001; 4: 181-5.
103. Voinnet O. RNA silencing as a plant immune system against viruses. Trends Genet. 2001; 17: 449-59.
104. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002; 418: 38-9.
105. McCown M, Diamond MS, Pekosz A. Small interfering RNAs block gene expression and production of negative and positive strand RNA viruses. 2003; (in press).
106. Coburn GA, Cullen BR. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol. 2002; 76: 9225-31.
107. Kitabwalla M, Ruprecht RM. RNA interference - a new weapon against HIV and beyond. N. Engl. J. Med. 2002; 347: 1364-7.
108. Lee NS, Dohjima T, Bauer G et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 2002; 20: 500-5.
109. Martinez MA, Gutierrez A, Armand-Ugon M et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002; 16: 2385-90.
110. Novina CD, Murray MF, Dykxhoorn DM et al. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 2002; 8: 681-6.
111. Yelina NE, Savenkov EI, Solovyev AG, Morozov SY, Valkonen JP. Long-distance movement, virulence, and RNA silencing suppression controlled by a single protein in hordei- and poty-viruses: complementary functions between virus families. J. Virol. 2002; 76: 12 981-91.
112. Bassett SE, Thomas DL, Brasky KM, Lanford RE. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J. Virol. 1999; 73: 1118-26.
113. Gaud U, Langer B, Petropoulou T, Thomas HC, Karayiannis P. Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects. J. Med. Virol. 2003; 69: 350-6.
114. Manzin A, Solforosi L, Petrelli E et al. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J. Virol. 1998; 72: 6271-6.
115. Smith DB. Evolution of the hypervariable region of hepatitis C virus. J. Viral Hepat. 1999; 6: 41-6.
116. van Doorn LJ, Capriles I, Maertens G et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J. Virol. 1995; 69: 773-8.
117. Wang WK, Lin SR, Lee CM, King CC, Chang SC. Dengue type 3 virus in plasma is a population of closely related genomes: quasispecies. J. Virol. 2002; 76: 4662-5.
118. Wang WK, Sung TL, Lee CN, Lin TY, King CC. Sequence diversity capsid gene nonstructural gene NS2B dengue-3 virus in vivo. Virology 2002; 303: 181-91.
119. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995; 375: 291-8.
120. Beasley DW, Barrett AD. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 2002; 76: 13 097-100.
121. Cecilia D, Gould EA. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology 1991; 181: 70-7.
122. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 2001; 75: 7769-73.
123. Holzmann H, Heinz FX, Mandl CW, Guirakhoo F, Kunz C. A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. J. Virol. 1990; 64: 5156-9.
124. Ryman KD, Ledger TN, Campbell GA, Watowich SJ, Barrett AD. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology 1998; 244: 59-65.
125. Thullier P, Demangel C, Bedouelle H et al. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J. Gen. Virol. 2001; 82: 1885-92.
126. Chambers TJ, Halevy M, Nestorowicz A, Rice CM, Lustig S. West Nile virus envelope proteins: nucleotide sequence analysis of strains differing in mouse neuroinvasiveness. J. Gen. Virol. 1998; 79: 2375-80.
127. Gao GF, Hussain MH, Reid HW, Gould EA. Identification of naturally occurring monoclonal antibody escape variants of louping ill virus. J. Gen. Virol. 1994; 75: 609-14.
128. Jennings AD, Gibson CA, Miller BR et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J. Infect. Dis. 1994; 169: 512-8.
129. Lin B, Parrish CR, Murray JM, Wright PJ. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 1994; 202: 885-90.
130. Lok SM, Ng ML, Aaskov J. Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody. J. Med. Virol. 2001; 65: 315-23.
131. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Mol. Med. Today 2000; 6: 365-72.
132. Kotwal GJ. Poxviral mimicry of complement and chemokine system components: what's the end game? Immunol. Today 2000; 21: 242-8.
133. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu. Rev. Immunol. 2000; 18: 861-926.
134. Cardosa MJ, Gordon S, Hirsch S, Springer TA, Porterfield JS. Interaction of West Nile virus with primary murine macrophages: role of cell activation and receptors for antibody and complement. J. Virol. 1986; 57: 952-9.
135. Cardosa MJ, Porterfield JS, Gordon S. Complement receptor mediates enhanced flavivirus replication in macrophages. J. Exp. Med. 1983; 158: 258-63.
136. Halstead SB, Porterfield JS, O'Rourke EJ. Enhancement of dengue virus infection in monocytes by flavivirus antisera. Am. J. Trop. Med. Hyg. 1980; 29: 638-42.
137. Gollins S, Porterfield J. Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody and viral fate. J .Gen. Virol. 1984; 65: 1261-72.
138. Gollins SW, Porterfield JS. Flavivirus infection enhancement in macrophages: an electron microscopic study of viral entry. J. Gen. Virol. 1985; 66: 1969-82.
139. Gould EA, Buckley A, Groeger BK, Cane PA, Doenhoff M. Immune enhancement of yellow fever virus neurovirulence for mice: studies of mechanisms involved. J. Gen. Virol. 1987; 68: 3105-12.
140. Gould EA, Buckley A. Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J. Gen. Virol. 1989; 70: 1605-8.
141. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 1979; 140: 527-33.
142. Kreil TR, Eibl MM. Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J. Virol. 1997; 71: 2921-7.
143. Peiris JS, Porterfield JS. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature 1979; 282: 509-11.
144. Phillpotts RJ, Stephenson JR, Porterfield JS. Antibody-dependent enhancement of tick-borne encephalitis virus infectivity. J. Gen. Virol. 1985; 66: 1831-7.
145. Brandt WE, McCown JM, Gentry MK, Russell PK. Infection enhancement of dengue type 2 virus in the U-937 human monocyte cell line by antibodies to flavivirus cross-reactive determinants. Infect. Immun. 1982; 36: 1036-41.
146. Mady BJ, Erbe DV, Kurane I, Fanger MW, Ennis FA. Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors. J. Immunol. 1991; 147: 3139-44.
147. Mady BJ, Kurane I, Erbe DV, Fanger MW, Ennis FA. Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancement of dengue virus infection. J. Gen. Virol. 1993; 74: 839-44.
148. Vaughn DW, Green S, Kalayanarooj S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 2000; 181: 2-9.
149. Vaughn DW, Green S, Kalayanarooj S et al. Dengue in the early febrile phase: viremia and antibody responses. J. Infect. Dis. 1997; 176: 322-30.
150. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev. Infect. Dis. 1989; 11: S830-9.
151. Lidbury BA, Mahalingam S. Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J. Virol. 2000; 74: 8376-81.
152. Mahalingam S, Lidbury BA. Suppression of lipopolysaccharide-induced antiviral transcription factor (STAT-1 and NF-kappa B) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proc. Natl Acad. Sci. USA 2002; 99: 13 819-24.
153. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 1996; 17: 131-7.
154. Farrell HE, Davis-Poynter NJ. From sabotage to camouflage: viral evasion of cytotoxic T lymphocyte and natural killer cell-mediated immunity. Semin. Cell Dev. Biol. 1998; 9: 369-78.
155. Fruh K, Gruhler A, Krishna RM, Schoenhals GJ. A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Immunol. Rev. 1999; 168: 157-66.
156. Ploegh HL. Viral strategies of immune evasion. Science 1998; 280: 248-53.
157. Yewdell JW, Hill AB. Viral interference with antigen presentation. Nat. Immunol. 2002; 3: 1019-25.
158. Lorenzo ME, Ploegh HL, Timbassi RS. Viral immune evasion strategies and the underlying cell biology. Semin. Immunol. 2001; 13: 1-9.
159. Eckels DD, Zhou H, Bian TH, Wang H. Identification of antigenic escape variants in an immunodominant epitope of hepatitis C virus. Int. Immunol. 1999; 11: 577-83.
160. Wang H, Bian T, Merrill SJ, Eckels DD. Sequence variation in the gene encoding the nonstructural 3 protein of hepatitis C virus: evidence for immune selection. J. Mol. Evol. 2002; 54: 465-73.
161. Wang H, Eckels DD. Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition. J. Immunol. 1999; 162: 4177-83.
162. Green S, Kurane I, Pincus S, Paoletti E, Ennis FA. Recognition of dengue virus NS1-NS2a proteins by human CD4+ cytotoxic T lymphocyte clones. Virology 1997; 234: 383-6.
163. Hill AB, Mullbacher A, Parrish C, Coia G, Westaway EG, Blanden RV. Broad cross-reactivity with marked fine specificity in the cytotoxic T cell response to flaviviruses. J. Gen. Virol. 1992; 73: 1115-23.
164. Kurane I, Dai LC, Livingston PG, Reed E, Ennis FA. Definition of an HLA-DPw2-restricted epitope on NS3, recognized by a dengue virus serotype-cross-reactive human CD4+ CD8- cytotoxic T-cell clone. J. Virol. 1993; 67: 6285-8.
165. Kurane I, Okamoto Y, Dai LC, Zeng LL, Brinton MA, Ennis FA. Flavivirus-cross-reactive, HLA-DR15-restricted epitope on NS3 recognized by human CD4+ CD8- cytotoxic T lymphocyte clones. J. Gen. Virol. 1995; 76: 2243-9.
166. Kurane I, Zeng L, Brinton MA, Ennis FA. Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2, 3, and 4. Virology 1998; 240: 169-74.
167. Mathews JH, Allan JE, Roehrig JT, Brubaker JR, Uren MF, Hunt AR. T-helper cell and associated antibody response to synthetic peptides of the E glycoprotein of Murray Valley encephalitis virus. J. Virol. 1991; 65: 5141-8.
168. Mathews JH, Roehrig JI, Brubaker JR, Hunt AR, Allan JE. A synthetic peptide to the E glycoprotein of Murray Valley encephalitis virus defines multiple virus-reactive T- and B-cell epitopes. J. Virol. 1992; 66: 6555-62.
169. Roehrig JT, Risi PA, Brubaker JR et al. T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus. Virology 1994; 198: 31-8.
170. Spaulding AC, Kurane I, Ennis FA, Rothman AL. Analysis of murine CD8 (+) T-cell clones specific for the Dengue virus NS3 protein: Flavivirus cross-reactivity and influence of infecting serotype. J. Virol. 1999; 73: 398-403.
171. Orange JS, Fassett MS, Koopman LA, Boyson JE, Strominger JL. Viral evasion of natural killer cells. Nat. Immunol. 2002; 3: 1006-12.
172. Smith HR, Idris AH, Yokoyama WM. Murine natural killer cell activation receptors. Immunol. Rev. 2001; 181: 115-25.
173. Mandelboim O, Lieberman N, Lev M et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409: 1055-60.
174. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002; 296: 1323-6.
175. Smith HR, Heusel JW, Mehta IK et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc. Natl Acad. Sci. USA 2002; 99: 8826-31.
176. King NJ, Kesson AM. Interferon-independent increases in class I major histocompatibility complex antigen expression follow flavivirus infection. J. Gen. Virol. 1988; 69: 2535-43.
177. King NJ, Maxwell LE, Kesson AM. Induction of class I major histocompatibility complex antigen expression by West Nile virus on gamma interferon-refractory early murine trophoblast cells. Proc. Natl Acad. Sci. USA 1989; 86: 911-5.
178. Liu Y, King N, Kesson A, Blanden RV, Mullbacher A. Flavivirus infection up-regulates the expression of class I and class II major histocompatibility antigens on and enhances T cell recognition of astrocytes in vitro. J. Neuroimmunol. 1989; 21: 157-68.
179. Liu Y, King N, Kesson A, Blanden RV, Mullbacher A. West Nile virus infection modulates the expression of class I and class II MHC antigens on astrocytes in vitro. Ann. NY Acad. Sci. 1988; 540: 483-5.
180. Lobigs M, Blanden RV, Mullbacher A. Flavivirus-induced up-regulation of MHC class I antigens; implications for the induction of CD8+ T-cell-mediated autoimmunity. Immunol. Rev. 1996; 152: 5-19.
181. Momburg F, Mullbacher A, Lobigs M. Modulation of transporter associated with antigen processing (TAP)-mediated peptide import into the endoplasmic reticulum by flavivirus infection. J. Virol. 2001; 75: 5663-71.
182. Kesson AM, King NJ. Transcriptional regulation of major histocompatibility complex class I by flavivirus West Nile is dependent on NF-kappaB activation. J. Infect. Dis. 2001; 184: 947-54.
183. Lobigs M, Mullbacher A, Blanden RV, Hammerling GJ, Momburg F. Antigen presentation in syrian hamster cells: substrate selectivity of TAP controlled by polymorphic residues in TAP1 and differential requirements for loading of H2 class I molecules. Immunogenetics 1999; 49: 931-41.
184. Mullbacher A, Lobigs M. Up-regulation of MHC class I by flavivirus-induced peptide translocation into the endoplasmic reticulum. Immunity 1995; 3: 207-14.
185. Crotta S, Stilla A, Wack A et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 2002; 195: 35-41.
186. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 2002; 195: 43-9.
187. Alexander JM, Nelson CA, van Berkel V et al. Structural basis of chemokine sequestration by a herpesvirus decoy receptor. Cell 2002; 111: 343-56.